ArticleEndocrine2025
Prognostic impact and clinical staging adjustment of tumor deposits in postoperative radioiodine therapy for differentiated thyroid cancer.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the prognostic significance of tumor deposits (TD) in patients with differentiated thyroid cancer (DTC) undergoing postoperative radioiodine (RAI) therapy. Additionally, it explored the potential role of TD in refining the TNM staging system.
methodsA retrospective analysis was performed on 11,278 thyroid cancer patients who underwent surgery. After applying stringent inclusion and exclusion criteria, 2162 patients were included in the final analysis. The association between TD and various clinicopathological characteristics was assessed. Propensity Score Matching (PSM) was employed to minimize selection bias, comparing outcomes between TD-positive [TD(+)] and TD-negative [TD(-)] groups. Kaplan-Meier survival analysis was utilized to estimate cumulative incidence rate of excellent response (ER) to RAI therapy. Prognostic comparisons were conducted by stratifying patients based on TD and lymph node (LN) status. Furthermore, a novel staging system incorporating TD status into the N stage of the TNM system was developed, and its prognostic accuracy was evaluated.
resultsOut of the 11,278 patients, 235 (2.08%) were identified as TD(+). In the 2162 patients analyzed, TD was significantly associated with T stage, N stage, extrathyroidal invasion, cumulative RAI dose, preablative stimulated thyroglobulin (Ps-Tg) levels, lymph node metastasis (LNM) count, primary tumor multiplicity, and maximum tumor diameter. Using a (1:2) PSM strategy, 95 TD(+) patients were matched with 185 TD(-) counterparts. Kaplan-Meier analysis revealed a significant difference in treatment outcomes between TD(+) and TD(-) groups (40.0% vs. 62.7%, P = 0.001). When comparing LN(+)TD(-) and LN(-)TD(+), no significant difference in outcomes was observed (59.8% vs. 44.4%, P = 0.235). However, outcomes differed significantly between LN(+)TD(+) and LN(+)TD(-) groups (39.5% vs. 59.8%, P = 0.004). No significant difference was noted between LN(+)TD(+) and LN(-)TD(+) groups (39.5% vs. 44.4%, P = 0.974). In N0 and N1a stages, TD(+) patients had significantly poorer prognoses compared to TD(-) patients (44.4% vs. 93.8%, P = 0.029 and 42.4% vs. 77.6%, P < 0.001, respectively). However, in the N1b stage, there was no significant difference between TD(+) and TD(-) groups (37.3% vs. 48.0%, P = 0.229). Interestingly, TD(+) patients in N0 and N1a stages exhibited outcomes comparable to N1b stage patients (44.4% vs. 44.5%, P = 0.603 and 42.4% vs. 44.5%, P = 0.108, respectively).
conclusionThe presence of TD significantly affected the prognosis of DTC patients undergoing postoperative RAI therapy and should be considered an essential factor in assessing patient prognosis. Incorporating TD status into the TNM staging system is recommended, with TD(+) patients proposed to be classified under the N1b stage.
Indexed as
Identifiers
40616765What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.